NCT02424916View on ClinicalTrials.gov

Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 26, 2015

Primary Completion Date

May 6, 2019

Study Completion Date

May 6, 2019

Conditions
Metastatic Melanoma
Interventions
BIOLOGICAL

Melanoma antigens-specific CD8+ T lymphocytes

The intervention uses an autologous somatic cell therapy medicinal product. It consists in the intravenous injection of melanoma antigens (Melan-A and MELOE-1) - specific CD8+ T lymphocytes followed by subcutaneous injections of Proleukin.

Trial Locations (1)

44000

Nantes University Hospital, Nantes

All Listed Sponsors
collaborator

UMR892

UNKNOWN

lead

Nantes University Hospital

OTHER

NCT02424916 - Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study | Biotech Hunter | Biotech Hunter